The new COO worked at at Wright for 2 years as the VP of international operations and has 17 years experience at medical companies.
The company said it landed FDA clearance in the U.S. and the CE Mark in the EU for its TxCell scanning laser delivery system, which would help physicians deliver the laser in a multi-spot scanning mode for the treatment of serious retinal diseases, according to a press release.
The market for hip and knee implants is stable but mired in a low-growth stage, according to analysts who attended the American Academy of Orthopedic Surgeons conference in San Francisco last week.
Although the abrupt departure of Stryker CEO Steve MacMillan drew the lion’s share of attention at the AAOS event, analysts from Barclays Capital and Leerink Swann agreed that the sector’s outlook calls for low-single-digit growth.
The deal is expected to advance Cutera’s place in the $1 billion global aesthetic business market, expanding the company’s presence in the vascular aesthetic sector while allowing Iridex room to focus on laser eye treatments.
Lower margins for Smith & Nephew’s (NYSE:SNN) bread-and-butter orthopedics division drove the British company’s third-quarter profits down nearly 3 percent for the three months ended Oct. 1.
Smith & Nephew posted profits of $133 million, or 14.9 cents per share, on sales of $1.03 billion for the quarter – a top-line increase of 9.7 percent when compared with the $941 million in revenues reported for the same period last year. But Q3 2010 profits were $137 million, or 15.4 cents per share.
InVivo Therapeutics Holdings Corp. (OTC:NVIV) appointed spinal cord injury expert Dr. Edward Wirth as its new chief scientist.
InVivo brings Wirth to the team as its waiting for a green light by the FDA to begin human trials of its biodegradable scaffold for treating spinal cord injury.
The scaffold is designed to protect and support spinal tissue and prevent secondary injury, including inflammation and glial scarring, following traumatic spinal cord injury.
Former Boston Scientific Corp. (NYSE:BSX) CEO James Tobin joined the board of directors at Aptus Endosystems Inc., a device company specializing in treating abdominal aortic aneurysms.
Tobin made quite a name for himself while occupying the corner office at med-tech giant Boston Scientific, where he was chief for a decade. He officially retired in July 2009 and was succeeded by Ray Elliott.
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Iridex Corp. (NSDQ:IRIX) nabbed approval from the Japan Ministry of Health, Labor and Welfare for its extended family of EndoProbe laser delivery devices.
The Mountain View, Calif.-based ophthalmic device maker isn’t letting the grass grow under its feet, announcing the concomitant launch of the devices in Japan as well.
The newly approved surgical tools are an intraocular laser delivery device used during vitreo-retinal surgery for the treatment of disorders including diabetic retinopathy, retinal detachments and vitreous hemorrhage.